Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 21, 2014

View Archived Issues

Tumor profiling service could help determine optimal therapy for urothelial carcinoma

Scientists develop plant-derived immunogenic vaccine for atherosclerosis

Nuvo Research sells Pennsaid 2% U.S. rights to Horizon Pharma

Batu Biologics signs license agreement with UC San Diego

Results from the first study of fidaxomicin in pediatric patients with CDAD

Fispemifene licensed to Apricus Biosciences

HMB-45 staining increases after UVB treatment for vitiligo

Cystic fibrosis candidate N-6022 well tolerated in phase I study

First-in-human results on Novartis new antimalarial drug candidate

Takeda Pharmaceutical confirms U.S. launch of Contrave

Baxter launches Hyqvia in the U.S. for adults with primary immunodeficiency

NewLink Genetics enters into exclusive worldwide licensing agreement for NLG-919

FDA grants fast track designation to TAS-102 for refractory metastatic colorectal cancer

Matinas BioPharma submits IND for MAT-9001 for severe hypertriglyceridemia

Pharmacyclics files sNDA for Imbruvica for Waldenstrom's macroglobulinemia

FDA accepts for review a BLA for pediatric hexavalent vaccine

EMA grants orphan drug designation to isactuzumab govitecan

CK18 as a potential predictor of type 2 diabetes in patients with NAFLD

Taisho submits Japanese filing for esflurbiprofen patch for osteoarthritis

GLPG-1205 demonstrates good safety in a phase I study

TesoRx and Aspen sign license agreement for bio-identical oral testosterone replacement therapy

FDA advisory committee recommends approval of secukinumab for plaque psoriasis

FDA approves Xiaflex to treat up to two joints in Dupuytren's contracture

Ofev launched in U.S.

RegeneRx allowed to advance RGN-259 into phase III for neurotrophic keratopathy

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 18, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...